Cargando…
Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor?
Tyrosine kinase receptor inhibitors (TKIs) are a relatively new class of targeted anti-cancer agents with vascular endothelial growth factor signalling pathway–inhibiting properties. Hypertension is recognized as one of the most common adverse effects of this anti-angiogenic therapy and is the conse...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857807/ https://www.ncbi.nlm.nih.gov/pubmed/33564402 http://dx.doi.org/10.1093/ckj/sfaa174 |